Prevention of Cholestatic Liver Disease Through BCL6-FXR Enterohepatic Crosstalk.

Cell Mol Gastroenterol Hepatol · 2026 · PMC12865649 · PMID 41389875

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

a strong trendP = .06so close (0.05 < p ≤ 0.1)

In females, dual-loss of hepatic Bcl6 and Fxr similarly caused ∼5-fold elevations in serum BAs, a strong trend towards increased liver BAs ( P = .06), and no change in serum cholesterol or triglycerides compared with Fxr KO females ( Figure 10 A–D ).

also in 1,799 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.